New immunotherapeutic approaches in oncology and hematology
Copyright © 2015 Elsevier Masson SAS. All rights reserved..
Scientific advances in the last decade have demonstrated the critical role of host immune system in the elimination and suppression of cancer cells. Better knowledge of signaling pathways has enabled the development of new cancer immunotherapy. The discovery of negative feedback mechanisms following the lymphocyte activation has promoted the development of new antibodies targeting molecule inhibitors such as PD1, PDL1 or CTLA-4. Dramatic results were obtained with melanoma. Checkpoint inhibitors (pembrolizumab and ipilimumab) have many advantages in terms of rate of objective response and overall survival. Recent studies in translational research aimed to understand and analyze mechanisms of action of anti-PD1/anti-PDL1. Expression of PDL1 in the tumor is associated with a significantly greater objective response rate (immunohistochemistry). Nevertheless, limits with tumor immunohistochemical analysis encourage new biomarkers research. Other immunotherapy approaches, such as cell and gene therapies using engineered T cells call for further advancements to broaden their applicability. However, these therapies are very expensive and their manufacturing process very restrictive, which could lately limit their use in case of inefficiency of checkpoint inhibitors or when lymphocytic infiltration in tumor is absent. In this case, the objective would be to engineer ex vivo the patient's immune system by restoring the ability of T cells to identify and suppress tumor cells. Currently, two gene-reprogramming tools are under development: chimeric antigen receptor and TCR modified T cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine - 22(2015), 3 vom: 09. Aug., Seite 132-40 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Nouvelles approches d'immunothérapie en onco-hématologie |
|---|
| Beteiligte Personen: |
Kroemer, M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.06.2016 Date Revised 03.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tracli.2015.05.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM24990389X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM24990389X | ||
| 003 | DE-627 | ||
| 005 | 20231224154602.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.tracli.2015.05.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0833.xml |
| 035 | |a (DE-627)NLM24990389X | ||
| 035 | |a (NLM)26068883 | ||
| 035 | |a (PII)S1246-7820(15)00031-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Kroemer, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New immunotherapeutic approaches in oncology and hematology |
| 246 | 3 | 3 | |a Nouvelles approches d'immunothérapie en onco-hématologie |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.06.2016 | ||
| 500 | |a Date Revised 03.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2015 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Scientific advances in the last decade have demonstrated the critical role of host immune system in the elimination and suppression of cancer cells. Better knowledge of signaling pathways has enabled the development of new cancer immunotherapy. The discovery of negative feedback mechanisms following the lymphocyte activation has promoted the development of new antibodies targeting molecule inhibitors such as PD1, PDL1 or CTLA-4. Dramatic results were obtained with melanoma. Checkpoint inhibitors (pembrolizumab and ipilimumab) have many advantages in terms of rate of objective response and overall survival. Recent studies in translational research aimed to understand and analyze mechanisms of action of anti-PD1/anti-PDL1. Expression of PDL1 in the tumor is associated with a significantly greater objective response rate (immunohistochemistry). Nevertheless, limits with tumor immunohistochemical analysis encourage new biomarkers research. Other immunotherapy approaches, such as cell and gene therapies using engineered T cells call for further advancements to broaden their applicability. However, these therapies are very expensive and their manufacturing process very restrictive, which could lately limit their use in case of inefficiency of checkpoint inhibitors or when lymphocytic infiltration in tumor is absent. In this case, the objective would be to engineer ex vivo the patient's immune system by restoring the ability of T cells to identify and suppress tumor cells. Currently, two gene-reprogramming tools are under development: chimeric antigen receptor and TCR modified T cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Checkpoint inhibitors | |
| 650 | 4 | |a Chimeric antigen receptor | |
| 650 | 4 | |a Immunomodulateurs | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Immunothérapie | |
| 650 | 4 | |a Récepteur antigénique chimérique | |
| 650 | 4 | |a TCR modified T cells | |
| 650 | 4 | |a TCR transgénique | |
| 650 | 7 | |a CD19-specific chimeric antigen receptor |2 NLM | |
| 650 | 7 | |a CD3 Complex |2 NLM | |
| 650 | 7 | |a CD3 antigen, zeta chain |2 NLM | |
| 650 | 7 | |a Immunoglobulin Heavy Chains |2 NLM | |
| 650 | 7 | |a Immunoglobulin Light Chains |2 NLM | |
| 650 | 7 | |a Immunoglobulin Variable Region |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell, alpha-beta |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 650 | 7 | |a Single-Chain Antibodies |2 NLM | |
| 700 | 1 | |a Turco, C |e verfasserin |4 aut | |
| 700 | 1 | |a Galaine, J |e verfasserin |4 aut | |
| 700 | 1 | |a Deschamps, M |e verfasserin |4 aut | |
| 700 | 1 | |a Limat, S |e verfasserin |4 aut | |
| 700 | 1 | |a Borg, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine |d 1994 |g 22(2015), 3 vom: 09. Aug., Seite 132-40 |w (DE-627)NLM074905449 |x 1953-8022 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2015 |g number:3 |g day:09 |g month:08 |g pages:132-40 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tracli.2015.05.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2015 |e 3 |b 09 |c 08 |h 132-40 | ||